FOR IMMEDIATE RELEASE
April 2016

MEDIA CONTACT:
Amanda Orloske
Marketing Manager, Unigen
Phone: 360.486.7441
Email: AOrloske@Unigen.net

New Publication on Univestin® Looks at Effects on Specific Systems
Unigen, Inc. has published a study showing Univestin has no adverse effects on the Cardiovascular, Respiratory and Central Nervous Systems.

Seattle, WA: Univestin has been available in the joint health supplement space through many finished products for over 10 years. In that time, Unigen, Inc. has not stopped their research on the proprietary ingredient. In fact they have conducted more than fifteen studies, ranging from discovery to human clinical trials. Unigen’s commercial partners have also conducted their own studies during that time, making the body of research impressive.

In this new publication, Unigen took a more specific look at Univestin’s effect on the cardiovascular, respiratory, and central nervous systems. In continued support for the third prong of the Univestin triple play, Long-Term Safety, the study found no adverse effects on these systems at levels much greater than suggested serving size for human consumption.

R. Grant Bergstrom, VP of Sales & Marketing says, “This is yet one more step in the journey of fulfilling our mission of “Bringing the best of nature to humankind”. We don’t launch an ingredient and then count our work as done. We continue to support these products, and our partners through continued research and marketing.”

The article has been published in Regulatory Toxicology and Pharmacology, Issue 77, pages 184-191. If you would like to read the full text of the publication, it can be found at the below link. Free access is available until May 15, 2016.

http://authors.elsevier.com/a/1SmWV~81l44Ot

###

About Unigen
Unigen discovers, develops and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through our high throughput screening PhytoLogix™ approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. Mechanism of action, safety and efficacy are documented with extensive preclinical in vitro and in vivo testing and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories, and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply.
alliances with commercial partners engaged in the manufacture, distribution and marketing of end-products in each of Unigen’s target markets. www.Unigen.net